Stay ahead of regulatory changes with expert insights on the evolving General Pharmaceutical Legislation and the wide-reaching impact of Most-Favoured-Nations (MFN) clauses. Gain actionable guidance from the EU Commission, EMA, and top pharma leaders to navigate today’s complex and dynamic landscape with confidence

Regulatory Frameworks | What's On?

Key insights into the EU Commission’s perspective on European competitiveness
The implications of US manufacturing policies on critical medicines 
Repercussions of US policy on pricing and reimbursement   
How can manufacturers balancing the EU Life Science Strategy with US policies?

How will the Biotech Act simplify clinical trials and unlock funding mechanisms?
HTA Regulation: aligning market access, pricing, and reimbursement strategies
Critical Medicines Act: new obligations for launch, supply, and notifications
Latest on streamlining EU MDR, IVDR, and AI Act for industry efficiency